Schedule at a Glance
Friday, March 14, 2025
| 12:00-5:00 | Registration Open |
| 2:00 – 5:00 | Workshop: LLMs and Generative AI: Real-world Applications from Peers Host: Lixia Yao Room: Centennial I Presenter: Yugang Jia, Zhiwei Yin, Si Chen, Ying Zhou, Lixia Yao, Farhat Siddiqui |
| 3:00 – 6:00 | High School Students Business Pitch Competition: Host: Xinjun Zhang Room: Centennial II Presenter: High School Students |
| 6:00 – 9:00 | President Reception: Invitation Only Host: Yufeng Li |
Saturday, March 15, 2025
| 8:00 – 9:00 | Registration Open |
| 9:00 – 10:30 |
Plenary SessionHost: Yufeng Li & Lu Wang |
| 10:30 – 10:50 | Coffee Break |
| 10:50 – 12:20 |
Parallel Sessions 1 |
| 12:20 – 1:30 | Lunch Break |
| 12:30 – 1:30 | Lunch Seminar YC Low, Sr. BD Manager, GenScript (Haverford) |
| 1:30 – 3:00 |
Parallel Sessions 2 |
| 3:00 – 4:00 | Coffee Break |
| 3:15 – 3:45 | Poster Presentation |
| 4:00 – 5:30 |
Parallel Sessions 3 |
| 5:30-5:45 | Rewarding Ceremony and Closing Remarks |
| 5:45-6:45 | Reception (5min Raffle drawing) |
Parallel Sessions:
Parallel Session 1 |
New Therapeutic Modalities and Platforms |
| 10:50-11:10 | Engineered CRISPR systems for diseases treatment Xue (Sherry) Gao, Ph.D., University of Pennsylvania |
| 11:10-11:40 | Universal Cancer Only Marker (UCOM), An Achievable Dream Needs U COM Wenqiang Yu, M.D., Ph.D., Fudan University |
| 11:40-12:20 | Risk factor analysis and risk prediction by machine learning Alex Qiu, M.D., Ph.D., Bristol Myers Squibb |
Parallel Session 2 |
Discovery & Development of Novel Antibody Drug Conjugates |
| 1:30-2:00 | Accelerating the development of ADCs from concept to BLA Jimmy Li, Ph.D., WuXi XDC |
| 2:00-2:30 | The Use of Computational and Machine Learning/AI Methods In The Development of Therapeutics for Oncology Dowdy Jackson, Ph.D., Jackson Consulting Group |
| 2:30-3:00 | OBI ADC Technology and Pipeline Xiao Meng, Ph.D., OBI Pharma |
Parallel Session 3 |
Advanced Drug Discovery and Processing Development |
| 4:00-4:30 | Targeted Protein Degradation in Oncology and Beyond Shuichan Xu, Ph.D., Bristol Myers Squibb |
| 4:30-5:00 | TBD Bo Zhai, Ph.D., Johnson & Johnson Innovative Medicine |
| 5:00-5:30 | Controls in Place for Prefilled Syringe Needle Clogging through Development, Validation and Manufacturing Qihang (Echo) Sun, Ph.D., Merck & Co., Inc. |
Parallel Session 1 |
Quantitative Medicine in Drug Development and Approval |
| 10:50-11:10 | TBD Suzette Girgis, Ph.D. M.S., Jazz Pharmaceuticals |
| 11:10-11:40 | Development of tRNA therapeutics to Treat Stop Codon Disease: Getting Quantitative Medicine into Action Sandra Visser, Ph.D., Alltrna |
| 11:40-12:20 | TBD Ercem Atillasoy, M.D., Jazz Pharmaceuticals |
Parallel Session 2 |
Enhancing Trial Outcomes |
| 1:30-2:00 | Implementing ML-driven inclusion criteria to enrich clinical trials with patients exhibiting canonical symptom structures Sam Tomioka, M.S., Sumitomo Pharma America |
| 2:00-2:30 | Capturing the patient voice through the development of novel endpoints in precision trials Katherine Bevans, Ph.D., Johnson & Johnson Innovative Medicine |
| 2:30-3:00 | TBD Hong Xie, M.D., M.B.A., M.S. |
Parallel Session 3 |
Impact of Bioanalysis on Biotherapeutics Research and Development |
| 4:00-4:30 | Addressing PK assay questions for clinical pharmacologists: challenges and solutions in Biologics bioanalysis Huaping Tang, Ph.D., GlaxoSmithKline plc |
| 4:30-5:00 | Bioanalytical strategies for characterizing glucagon-like peptide-1 (GLP-1) based therapeutics Wenying Jian, Ph.D., Johnson & Johnson Innovative Medicine |
| 5:00-5:30 | Bioanalytic strategy for ADC Weifeng Xu, Ph.D., Merck & Co., Inc. |
Parallel Session 1 |
State-of-the-Art AI Technologies: Where We Are and Where We Are Heading |
| 10:50-11:10 | Generative AI applications in precision health Yugang Jia, Ph.D., Verily Life Science / MIT |
| 11:10-11:40 | Applications of Siamese Networks for Biomedical Text Processing Eric Yang, Ph.D., Medidata Solutions |
| 11:40-12:20 | Unleashing the Power of Data Science in Pharmaceutical Research in the Era of Artificial Intelligence Antong Chen, Ph.D., Merck & Co., Inc. |
Parallel Session 2 |
Data Science in Biopharma: Unlocking Insights from Big Data I |
| 1:30-2:00 | Debiased causal transformer for drug discovery using real-world data Yong Chen, Ph.D., University of Pennsylvania |
| 2:00-2:30 | Analyzing the large and complex SFARI autism cohort data using the Genotypes and Phenotypes in Families (GPF) platform Ivan Iossifov, Ph.D., CSHL |
| 2:30-3:00 | Real-World Data in Drug Discovery and Precision Medicine: Opportunities and Challenges Rong Chen, Ph.D., AbbVie Inc |
Parallel Session 3 |
Data Science in Biopharma: Unlocking Insights from Big Data II |
| 4:00-4:15 | Harnessing AI and Informatics for Precision Medicine in Dementia Li Shen, Ph.D., University of Pennsylvania |
| 4:15-4:30 | Unleashing the potential of unlabeled digital pathology data Lin Li, Ph.D., Merck & Co., Inc. |
| 4:30-4:45 | Optimizing Physician Selection: AI and Machine Learning Applications in Clinical Trials and Marketing Yunlong Wang, Ph.D., IQVIA |
| 4:45-5:00 | Uses of CausalAI for the Optimization of Clinical Trials Aaron Mackey, Ph.D., Lokavant |
| 5:00-5:30 | Panel Disccusion Li Shen, Lin Li, Yunlong Wang, Aaron Mackey |
Parallel Session 1 |
Going Global: Strategy vs Necessity |
| 10:50-12:20 | Panel Discussion Wendy Pan, JD Ph.D., Goodwin Procter LLP Lihua Zheng, JD Ph.D., Z-Star Therapeutics Inc. Marc Appel, JD M.B.A., Pacific Bridge NY Weiyong Sun, M.D. Ph.D. M.B.A., Hansoh Pharma |
Parallel Session 2 |
Going Global: The Making of a Global Ready Asset |
| 1:30-2:00 | Panel Discussion Shirley Liu, Ph.D., GV20Therapeutics Haichen Yang, M.D. M.B.A. M.A., Amicus Therapeutics Derek Yuan, Ph.D., LYFE Capital Yuenian Eric Shi, M.D. Ph.D., Chimigen Bio Richie Lou, BS, McKinsey & Company |
Parallel Session 3 |
Going Global: Finding Help in the US |
| 4:00-4:15 | Panel Discussion Stephen Manobianco, M.B.A., PSG Life Sciences Enna Weng, M.B.A., Freedom Capital Market Vikram Patra, M.B.A., Freedom Capital Market Joshua A. Kaufman, JD M.B.A., DLA Piper LLP (US) Colin Wang, Ph.D., 6 Dimensions Capital |
Parallel Session 2 |
From Conflict to Connection: Improving Your Career Soft Skills |
| 1:30-2:00 | Cross Culture Communication Patricia Tsao, M.D., Ph.D., M.P.H., CytoEX Inc. |
| 2:00-2:30 | Conflict Resolution Helen Sun, M.A., SPHR, Zambon Group |
| 2:30-3:00 | Ask Experts Patricia Tsao, Helen Sun, Evelyn Guo |